Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | JAK1 | P23458 | 3/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 5/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26633654 | 0.99 | JAK2 (0.47) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL26633657 | 0.98 | JAK2 (0.46) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL5874322 | 0.93 | JAK2 (0.44) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL2529921 | 0.87 | CA12 (0.54) | GPR119OPRD1OPRK1 | |
| SCHEMBL22509312 | 0.86 | OPRM1 (0.55) | JAK2JAK1GPR119 | |
| SCHEMBL3591187 | 0.86 | GPR119 (0.51) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL3160806 | 0.85 | OPRM1 (0.56) | GPR119 | |
| SCHEMBL1938611 | 0.85 | RORC (0.48) | JAK2JAK1GPR119 | |
| SCHEMBL3925930 | 0.85 | RORC (0.48) | JAK2JAK1 | |
| SCHEMBL651457 | 0.85 | OPRM1 (0.56) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114867720-B | Heteroaryl derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| EP-4092019-A1 | HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Zhejiang Hisun Pharmaceutical Co., Ltd. (CN) | 2022-11-23 | — | — | EP | disclosed |
| CN-114867720-A | Heteroaryl derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-8343999-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343999-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343999-B2 | Thiazolyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-05-13 | — | — | US | disclosed |
| WO-2008124757-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008124757-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-16 | — | — | WO | disclosed |
| US-5861416-A | TREATMENT OF ASTHMA OR COUGH | MERRELL PHARMACEUTICALS INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5824690-A | TREATING ASTHMA, COUGH | HOECHST MARION ROUSSEL INC. (US) | 1998-10-20 | — | — | US | disclosed |
| EP-0696280-B1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL PHARMA INC (US) | 1997-09-24 | — | — | EP | disclosed |
| US-5661160-A | ADMINISTERING AN ANTITUSSIVE AGENT FOR TREATING COUGH; TACHYKININ ANTAGONISM, SUBSTANCE P AND NEUROKININ A ANTAGONISM | MERRELL PHARMACEUTICALS INC. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5648366-A | TACHYKININ ANTAGONISTS USEFUL IN TREATING ASTHMA | MERRELL PHARMACEUTICALS INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5635510-A | TACHYKININ (ESPECIALLY SUBSTANCE P AND NEUROKININ A) ANTAGONISTS; ANTIINFLAMMATORY AGENTS, ANALGESICS; NERVOUS SYSTEM DISORDERS; BRONCHODILATOR AGENTS | MERRELL PHARMACEUTICALS INC. (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0696280-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMA (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994026735-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120770-A1 | THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS | TTBK1, ERBB2, TEC | JAK2 23/4885JAK1 4/4885GPR119 808/4885 |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | PTPN11, PTPN1, PTPN7 | JAK2 12/4885JAK1 27/4885GPR119 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.